Myriad Genetics, MYGN

Analyst Sees Bottom For Myriad Genetics Stock, Issues Upgrade
Piper Sandler upgrades Myriad Genetics to Overweight, citing stock stabilization and new leadership. The firm raises its price target to $12.50.
Piper Sandler Upgrades Myriad Genetics (MYGN)
Fintel reports that on March 12, 2025, Piper Sandler upgraded their outlook for Myriad Genetics (NasdaqGS:MYGN) from Neutral to Overweight. Analyst Price Forecast Suggests 84.10% Upside As of March 4,
Why Are Myriad Genetics (MYGN) Shares Soaring Today
What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 10.6% in the morning session after Piper Sandler analysts upgraded the stock's rating from Neutral to Buy. The improved outlook was based on expectations for MYGN's new CEO,
Myriad Genetics upgraded to Overweight from Neutral at Piper Sandler
Piper Sandler upgraded Myriad Genetics (MYGN) to Overweight from Neutral with a price target of $12.50, up from $11.50. The stock is down more
Myriad Genetics upgraded at Piper Sandler on balanced risk reward setup
Myriad Genetics (NASDAQ:MYGN) traded higher on Wednesday after Piper Sandler upgraded the cancer test developer to Overweight from Neutral and raised its price target by $1.00 to $12.50 per share, indicating a balanced risk-reward setup.
Why Myriad Genetics (MYGN) Shares Are Plunging Today
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 16.1% in the morning session after the company reported a tough quarter(Q4 2024), with revenue missing expectations and 2025 guidance for both revenue and EBITDA coming in light.
Myriad Genetics price target lowered to $16 from $21 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Myriad Genetics (MYGN) to $16 from $21 and keeps an Equal Weight rating on the shares after ...
Schaeffer's Investment Research2d
Medical Equipment Stock Jumps on Upgrade
Short sellers have been increasing their bets, with short interest now accounting for 6.1% of the stock's available float.
Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO
UnitedHealthcare will stop covering Myriad Genetics' GeneSight test in 2025, impacting $45 million in revenue. Myriad ...
UBS Group Issues Pessimistic Forecast for Myriad Genetics (NASDAQ:MYGN) Stock Price
Myriad Genetics (NASDAQ:MYGN – Get Free Report) had its price objective dropped by investment analysts at UBS Group from $18.00 to $16.00 in a note issued to investors on Tuesday,Benzinga reports. The ...